This message was sent to ##Email##
|
| October 25, 2017 |
| |  | | |
|
|
|
| |
The New York Times
The Food and Drug Administration recently approved the second in a radically new class of treatments that genetically reboot a patient's own immune cells to kill cancer. The new therapy, Yescarta, made by Kite Pharma, was approved for adults with aggressive forms of a blood cancer, non-Hodgkin's lymphoma, who have undergone two regimens of chemotherapy that failed.
READ MORE
| ASCT 2018 Annual Conference
|
ASCT
ASCT's upcoming annual conference will be here before you know it. Next year's conference will be held May 4-6 in Salt Lake City, Utah at the Hilton Salt Lake City Center. Don't miss this opportunity to connect with colleagues from across the country! This is the perfect location to combine your conference experience with a mini vacation. Salt Lake City has something for everyone from theatre and art to hiking and mountain biking. We're looking forward to exploring our host city and we can't wait to see you there!
 |
|
Surgilube® has been the preferred sterile lubricant in the medical community since 1932. It is the only sterile carbomer-free lubricant deemed appropriate for use by all leading Pap test manufacturers when a lubricant is necessary. Surgilube has undergone stringent and periodic testing and has met established quality parameters without impacting Pap test results.
|
|
| Date |
Event |
Location |
More information |
Jan. 17, 2018 |
Quantitative Cytology and its Emerging Role in Daily Practice
|
Your PC |
Liron Pantanowitz, MD
Professor of Pathology & Biomedical Informatics
Director of Pathology Informatics
Director of Cytopathology UPMC Shadyside
Director of Pathology Informatics Fellowship
Department of Pathology, UPMC Shadyside
Pittsburgh, PA
Details
|
June 20, 2018 |
The Bethesda System for Cervical Cytology — Update and Beyond
|
Your PC |
Patricia G. Tiscornia-Wasserman, MD
Professor of Pathology and Cell Biology
Director of Cytopathology
Columbia University Medical Center
Melville, New York
Details
|
Available for 6 months after subscribing |
Quality Assessment Center (QAC) Cell Blocks Basics Workbench
|
Your PC |
Details |
Available for 6 months after subscribing |
Quality Assessment Center (QAC)
Document Control for Cytopathology Workbench
|
Your PC |
Details |
Available for 6 months after subscribing |
Quality Assessment Center (QAC)
The LEAN Cytopathology Laboratory Workbench
|
Your PC |
Details |
Genetic Engineering & Biotechnology News
Genetic studies by scientists in the U.S. suggest that the most common form of ovarian cancer actually starts in the fallopian tubes and takes about 6.5 years to progress to high-grade serous ovarian carcinoma. Research leader Victor Velculescu, M.D., Ph.D., a professor of oncology at the Johns Hopkins Kimmel Cancer Center, says that data from their small-scale genetic analysis study could lead to new approaches to preventing, diagnosing, and potentially treating the disease.
READ MORE
Medpage Today
Men who smoked and had five or more lifetime oral sex partners had the highest prevalence of oral oncogenic human papilloma virus infection (14.9 percent), an epidemiological study found. Among women, smoking was not a significant risk factor, and multiple oral sex partners only modestly increased the prevalence of oral oncogenic HPV infection from 0.7 percent to 1.5 percent, reported researchers led by Amber D'Souza, PhD, of Johns Hopkins University in Baltimore.
READ MORE
Science Alert
In what's being billed as the world's largest collective study on the genetics of breast cancer, researchers have discovered 72 new gene variants that appear to be responsible for increasing the risk of developing the disease.
READ MORE
University of Surrey via Phys.org
Scientists from the University of Surrey have developed 'intelligent' nanoparticles which heat up to a temperature high enough to kill cancerous cells — but which then self-regulate and lose heat before they get hot enough to harm healthy tissue.
READ MORE
Dark Daily
Anatomic pathologists have experienced sustained cuts to reimbursements for both technical component and professional component services during the past eight to 10 years. But what has not happened to pathology is a 33 percent decline in the volume of biopsies referred to diagnosis. Yet that is what some studies say has happened to imaging reimbursement since 2006.
READ MORE
Cancer Therapy Advisor
The armory of drugs available to patients with advanced renal cell carcinoma has grown significantly in the last 10 years. Unfortunately, patients with locally advanced, non-metastatic RCC do not yet benefit from many of these advances. Surgery remains the best chance for a cure in this setting.
READ MORE
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
